Breaking News
Get 40% Off 0
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks. Unlock full list
Close

Natera Inc (NTRA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Natera Inc's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
108.51 +0.25    +0.23%
- Closed. Currency in USD ( Disclaimer )
After Hours
108.51
-0.00
-0.00%
- Real-time Data
Type:  Equity
Market:  United States
  • Volume: 634,951
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 107.87 - 110.09
Natera Inc 108.51 +0.25 +0.23%

Natera Inc Company Profile

 
Get an in-depth profile of Natera Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryHealthcare Providers & Services
SectorHealthcare
Employees

3288

Equity Type

ORD

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company’s algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Contact Information

Address 13011 McCallen Pass Building A
Suite 100 Austin, 78753
United States
Phone 650 980 9190
Fax -

Top Executives

Name Age Since Title
Roelof Frederik Botha 50 2007 Lead Independent Director
Matthew Rabinowitz 49 2005 Co-Founder & Executive Chairman
James Irvin Healy 58 2014 Independent Director
Herman Rosenman 76 2014 Independent Director
Gail B. Marcus 66 2017 Independent Director
Ruth Evelyn Williams-Brinkley 70 2023 Independent Director
Jonathan Sheena 50 2007 Co-Founder & Director
Steven Leonard Chapman 44 2017 CEO & Director
Rowan E. Chapman - 2019 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NTRA Comments

Write your thoughts about Natera Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Matt Georgopulos
opulo01 Jan 05, 2022 11:51PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Losing $4 per share every year shouldn't be worth $85 per share. Let me know when it get down to $20 and maybe I'll buy some. Prospects look good, but you have to make money to be worth something!
gerardo Galarza
gerardo Galarza Jan 05, 2022 11:51PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
it's close now. under 40 be ready
Peter Smith
Peter Smith Jan 08, 2021 9:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
the higher the loss, the higher the stock price...can please somebody explain that to me?
Matt Georgopulos
opulo01 Jan 08, 2021 9:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
How about now? Make more sense now? :)
Mi Michal
Mi Michal Jul 03, 2019 1:34AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Natera will further surge. In couple of months Natera will launch another new test Prospera!!
Carol Foulds
Carol Foulds Jul 03, 2019 1:34AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Any idea why it’sdropping this week. I don’t see any news. I have seem a couple of SEC divestments recently.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email